Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Shares Outstanding (Weighted Average) (2022 - 2024)

Adial Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $5.8 million for Q3 2024.

  • For Q3 2024, Shares Outstanding (Weighted Average) rose 395.16% year-over-year to $5.8 million; the TTM value through Sep 2024 reached $5.8 million, up 395.16%, while the annual FY2023 figure was $1.4 million, 42.25% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2024 was $5.8 million at Adial Pharmaceuticals, up from $4.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $23.2 million in Q1 2022 and bottomed at $972641.0 in Q2 2022.
  • The 3-year median for Shares Outstanding (Weighted Average) is $1.2 million (2023), against an average of $4.0 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) crashed 95.43% in 2023 before it soared 395.16% in 2024.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $1.0 million in 2022, then soared by 42.25% to $1.4 million in 2023, then surged by 309.62% to $5.8 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Shares Outstanding (Weighted Average) are $5.8 million (Q3 2024), $4.2 million (Q2 2024), and $3.0 million (Q1 2024).